Unity Biotechnology, Inc. (UBX) News

Unity Biotechnology, Inc. (UBX): $1.31

0.05 (-3.68%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add UBX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#49 of 360

in industry

Filter UBX News Items

UBX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

UBX News Highlights

  • UBX's 30 day story count now stands at 2.
  • Over the past 26 days, the trend for UBX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest UBX News From Around the Web

Below are the latest news stories about UNITY BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate UBX as an investment opportunity.

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

Topline 16-week data expected in the fourth quarter of 2024SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325 (foselutoclax), a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema

Yahoo | December 12, 2023

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | November 16, 2023

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023. “Following positive efficacy and safety data at 48 weeks from a single injection of UBX1325 (foselutoclax) in patients with diabetic macular edema, we are working to quickly and efficiently advance UBX1325 (foseluto

Yahoo | November 13, 2023

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,143,000 shares of common stock, having an exercise price of $8.50 per share, issued by UNITY on August 22, 2022, at a reduced e

Yahoo | November 10, 2023

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks

Here are the best longevity stocks to consider.

Matthew Farley on InvestorPlace | October 17, 2023

20 Foods Consumed By Longest Living People Every Day

In this article, we will be taking a look at the 20 foods consumed by longest living people every day. If you are not interested in the details about market insights on longevity, head straight to the 5 Foods Consumed By Longest Living People Every Day. The pursuit of longevity and vitality has captivated humankind […]

Yahoo | October 4, 2023

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease Patients with prior anti-VEGF treatment and switched to UBX1325 monotherapy at study start maintained visual acuity through 24 weeks and had only a 1.5 letter decrease from baseline at week 48 40% of UBX1325-treated patients did not require anti-VEGF treatment through 48 weeks and 64%

Yahoo | September 27, 2023

Unity Biotechnology Inc CEO Anirvan Ghosh Sells 1,246 Shares

On September 14, 2023, Anirvan Ghosh, the CEO of Unity Biotechnology Inc (NASDAQ:UBX), sold 1,246 shares of the company's stock.

Yahoo | September 16, 2023

20 States With The Longest Life Expectancy In America

In this article, we will be taking a look at the 20 states with the longest life expectancy in America. If you want to skip our detailed analysis of companies that are working on improving life expectancy, you can go directly to see the 5 States With The Longest Life Expectancy In America. Life Expectancy […]

Yahoo | August 15, 2023

UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023. “We are focused on rapidly advancing UBX1325 (foselutoclax) into the next clinical study to help patients suffering from diabetic macular edema who receive suboptimal benefit from the current anti-VEGF standard of care,

Yahoo | August 8, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!